Top Page
PTC Therapeutics
(NASDAQ:PTCT)
PTC Therapeutics (PTCT) vs. SPDR S&P 500 ETF (SPY)
PTC Therapeutics Business Overview & Revenue Model
PTC Therapeutics Key Performance Indicators (KPIs)
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Main Street DataPTC Therapeutics Earnings Call Summary
PTC Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.78B | 806.78M | 937.82M | 698.80M | 538.59M | 380.77M |
| Gross Profit | 1.62B | 749.38M | 872.34M | 654.12M | 506.26M | 361.82M |
| EBITDA | 911.78M | -120.46M | -330.34M | -367.78M | -368.18M | -303.09M |
| Net Income | 751.72M | -363.30M | -626.60M | -559.02M | -523.90M | -438.16M |
Balance Sheet | ||||||
| Total Assets | 2.64B | 1.71B | 1.90B | 1.71B | 1.94B | 2.21B |
| Cash, Cash Equivalents and Short-Term Investments | 1.71B | 1.14B | 876.74M | 410.70M | 773.38M | 1.10B |
| Total Debt | 2.49B | 2.47B | 2.23B | 1.46B | 1.27B | 420.44M |
| Total Liabilities | 2.80B | 2.80B | 2.71B | 2.05B | 1.94B | 1.73B |
| Stockholders Equity | -155.76M | -1.10B | -818.55M | -347.09M | 1.44M | 481.98M |
Cash Flow | ||||||
| Free Cash Flow | 699.00M | -181.94M | -279.04M | -509.11M | -336.66M | -250.05M |
| Operating Cash Flow | 715.47M | -107.69M | -158.42M | -356.65M | -251.33M | -194.07M |
| Investing Cash Flow | -628.28M | 44.18M | -176.74M | 290.18M | 219.18M | -561.55M |
| Financing Cash Flow | 55.06M | 255.87M | 646.40M | 167.95M | 20.88M | 668.72M |
PTC Therapeutics Technical Analysis
PTC Therapeutics Risk Analysis
PTC Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $6.07B | 8.84 | ― | ― | 97.54% | ― | |
65 Neutral | $4.82B | 10.92 | 111.96% | ― | 100.88% | ― | |
52 Neutral | $7.28B | ― | -51.57% | ― | 57.54% | -36.57% | |
52 Neutral | $5.22B | ― | -47.18% | ― | -76.96% | -425.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.36B | ― | -20.83% | ― | ― | -5.21% | |
40 Underperform | $4.83B | ― | -25.33% | ― | -81.10% | -99.21% |
PTC Therapeutics Corporate Events
PTC Therapeutics’ recent earnings call was marked by a strong positive sentiment, primarily fueled by the successful launch of Sephience and the company’s robust financial standing. However, the call also highlighted some challenges, particularly concerning government payer policy finalizations and uncertainties surrounding Emflaza’s future revenue potential.
PTC Therapeutics, Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders, leveraging its scientific expertise and commercial infrastructure to meet unmet medical needs.
On November 4, 2025, PTC Therapeutics announced its financial results for the third quarter of 2025, highlighting the successful global launch of Sephience™ (sepiapterin) in the US and EU, which generated $19.6 million in revenue. The company’s total revenue for the quarter was $211 million, with strong contributions from its Duchenne muscular dystrophy franchise. The launch of Sephience is anticipated to establish it as the standard of care for PKU, supporting PTC’s growth and market positioning. PTC also narrowed its full-year 2025 revenue guidance to $750-$800 million, reflecting its strategic focus on expanding its product portfolio and enhancing shareholder value.
The most recent analyst rating on (PTCT) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
PTC Therapeutics has completed a clinical study titled ‘An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age.’ The study aimed to assess the pharmacokinetics and safety of vatiquinone in young participants with Friedreich ataxia, a rare genetic disorder. This research is significant as it targets a vulnerable age group, potentially offering new treatment avenues.
On August 19, 2025, PTC Therapeutics announced that the FDA issued a Complete Response Letter regarding their New Drug Application for vatiquinone, a treatment for Friedreich’s ataxia. The FDA indicated that substantial evidence of efficacy was not demonstrated and requested an additional study. PTC plans to meet with the FDA to address these issues, reflecting the potential impact on their operations and market positioning.
The most recent analyst rating on (PTCT) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
PTC Therapeutics’ recent earnings call painted a picture of a company on the upswing, buoyed by the successful approval and launch of Sephience. This development is expected to significantly bolster future revenues. Despite facing challenges such as market erosion for Emflaza and uncertainties surrounding the vatiquinone NDA, the overall sentiment was positive, with the Sephience launch being a major highlight.
PTC Therapeutics, Inc. is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines for rare disorders, leveraging its scientific expertise and global infrastructure to provide treatments for patients with unmet medical needs.
On August 5, 2025, PTC Therapeutics entered into a Rights Satisfaction Agreement with former securityholders of Censa Pharmaceuticals, resulting in the cancellation of their rights to receive certain payments based on net sales of products containing sepiapterin. In exchange, PTC agreed to pay up to $250 million in cash and potential milestone payments based on sales thresholds. This agreement impacts the company’s financial obligations under the original merger agreement but maintains other rights and obligations intact.
The most recent analyst rating on (PTCT) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
On August 7, 2025, PTC Therapeutics announced its second quarter financial results and corporate updates, highlighting the European and FDA approval of Sephience™ for PKU, marking a significant milestone for the company. The global launch of Sephience is underway, expected to drive future growth and profitability. The company reported total revenues of $179 million for Q2 2025, with notable contributions from its DMD franchise and royalty revenues. Despite a decrease in net product revenue compared to the previous year, PTC’s strategic moves, including an agreement to purchase obligations related to Sephience, position it for continued expansion in the rare disease market.
The most recent analyst rating on (PTCT) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.